On January 5, 2022 Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, reported that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at the following virtual investor conferences in January (Press release, Candel Therapeutics, JAN 5, 2022, View Source [SID1234598261]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright BioConnect Conference
Format: Pre-recorded corporate presentation
Date/Time: January 10, 2022, on-demand viewing starts at 7:00 am ET
B. Riley Securities’ 2022 Oncology Conference
Format: Live corporate presentation
Date/Time: January 28, 2022, at 11:30 am ET
To access the webcasts or archived recordings of the company presentations, please visit the Candel Therapeutics website at View Source

On January 5, 2022 Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported the appointment of Mr. Kenneth Galbraith as Chair and Chief Executive Officer (CEO) of Zymeworks, effective on or before February 1, 2022 (Press release, Zymeworks, JAN 5, 2022, View Source [SID1234598283]). Mr. Galbraith will succeed Zymeworks co-founder Ali Tehrani, Ph.D., who has served as President and CEO since 2003. Dr. Tehrani will remain as an advisor to the Company to assist with the transition.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Ken Galbraith is an outstanding global leader who brings more than 30 years of life science industry, venture capital and commercialization experience to Zymeworks, along with a proven track record of strong leadership and operational skills," said Lota Zoth, Zymeworks’ current Board Chair. "The Board unanimously believes that Ken is the ideal leader to implement our next phase of development as we continue late-stage clinical trials for zanidatamab and expand our R&D pipeline. We thank and recognize Ali for his outstanding service in creating a solid foundation and advancing Zymeworks to a late-stage clinical company with valuable R&D programs, numerous productive pharmaceutical partnerships, and a high-quality management team."

A former Zymeworks Board member from 2009 to 2013, Ken Galbraith has been working since 1987 as a life sciences executive, director, investor and advisor in the growth of both private and public companies from early-stage through regulatory approval and commercialization. Most recently, he served as executive-in-residence with Syncona (LSE:SYNC), a large British closed-ended healthcare investment trust dedicated to life science investments. He began his biotechnology career in Vancouver as CFO at QLT, where he was instrumental in growing the company to over 500 employees while gaining market approvals for several new medicines prior to his departure in 2000. During his lengthy career, Ken has played a pivotal role in the development of several successful biotechnology companies throughout North America, including AnorMED, Macrogenics, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq and Angiotech, among others. He holds a Bachelor of Commerce degree with honors from the University of British Columbia.

"I have long believed in the potential of innovative technology platforms to generate novel multispecific antibodies and antibody-drug conjugates and transform the treatment of cancer. Zymeworks’ innovative approach, technology platforms and emerging product pipeline represent a tremendous opportunity, and I look forward to leading the Company during this exciting period of innovation in cancer therapies," said Ken Galbraith. "This year, we expect to progress our two ongoing pivotal clinical studies for zanidatamab, present important new data for zanidatamab and ZW49 to inform additional clinical development opportunities, further advance our preclinical product pipeline and gain insights from our pharmaceutical partners’ programs as they advance into and through clinical development."

The Company also announced that CFO Neil Klompas was promoted to the dual position of COO and CFO, effective immediately.

Ken Galbraith added, "Neil has been instrumental to the growth and financing of Zymeworks for 15 years, and I look forward to working closely with him, our employees, our partners and our Board of Directors to develop the next generation of biotherapeutics with the potential to improve outcomes for patients around the world with difficult-to-treat cancers."

On January 5, 2022 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, reported that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion (Press release, Thermo Fisher Scientific, JAN 5, 2022, View Source,-a-Leader-in-Recombinant-Proteins [SID1234598302]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based in Cranbury, New Jersey, PeproTech is a privately held provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors. Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models. PeproTech’s recombinant proteins portfolio complements Thermo Fisher’s cell culture media products and will enable Thermo Fisher to provide customers significant benefits through an integrated offering.

"PeproTech will be an excellent strategic fit within our biosciences business and will allow us to even better serve our pharma and biotech customers by adding new capabilities to our existing offering," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "In combination with our proprietary bioprocessing and cell culture technologies, this complementary transaction positions us to partner with our customers to drive the evolution of the fast-growing market for cell and gene therapies. By leveraging our commercial reach, we will be able to efficiently grow the PeproTech business and generate attractive financial results all while furthering our Mission to enable our customers to make the world healthier, cleaner and safer."

Casper added, "With more than three decades of experience across a broad range of applications for drug development and therapeutic products, the PeproTech team has built long-standing customer relationships in pharma and biotech and life sciences research. We look forward to welcoming their incredibly talented team to Thermo Fisher."

Bob Goldman, president and co-founder of PeproTech, commented, "We are pleased to join Thermo Fisher given their team’s outstanding industry leadership and shared commitment to develop innovative therapies that improve patient outcomes. PeproTech’s reputation for unparalleled product consistency and quality directly aligns with that of Thermo Fisher’s, and we look forward to building on our success as part of the world leader in serving science."

PeproTech will become part of the biosciences business within Thermo Fisher and will be integrated into the Life Sciences Solutions Segment.

On January 5, 2022 Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company, and Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, reported a partnership to develop the first single-cell, spatial multiomics workflow for comprehensive, unbiased analysis of tissue samples (Press release, Akoya Biosciences, JAN 5, 2022, View Source [SID1234598196]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this agreement, the partners will bring to the market an automated, spatial multiomics workflow that can perform rapid, in situ analysis of multiple analytes, at single cell resolution, across whole slides. Akoya’s PhenoCycler-Fusion System, due to launch in early January 2022, will run the company’s well-established protein imaging assays in addition to automating Advanced Cell Diagnostics’, a Bio-Techne brand, proven and highly cited RNAScope HiPlex v2 assay for RNA imaging. The partnership exemplifies the commitment of both companies to offer researchers greater access to innovative and open access solutions for spatial biology applications.

RNA and protein expression offer complementary insights into cell states and phenotypes. Combining the PhenoCycler-Fusion workflow with the RNAScope HiPlex v2 assay has the potential to accelerate scientific understanding of human health and complex diseases like cancer. Spatial multiomics approaches can also unlock new biomarker diagnostic signatures, enabling better stratification of patients and ultimately improving treatment outcomes.

Backed by over 4,500 peer-reviewed publications, RNAScope Assays are an established standard for spatial RNA imaging. Under the terms of the agreement, Akoya and Bio-Techne will develop and co-market protocols to enable automated workflows for running RNAScope assays on Akoya’s spatial phenotyping systems.

This new combined workflow complements Akoya’s spatial transcriptomics capabilities, currently under development, serving as an important validation tool for deep spatial phenotyping applications.

"The life sciences market has long needed an approach that provides an unbiased, multiomics view of tissue biology and architecture, which is critical for understanding complex mechanisms of disease and response to therapy," said Brian McKelligon, Chief Executive Officer of Akoya Biosciences. "The partnership with Bio-Techne, which revolutionized RNA in situ hybridization methods, can further empower researchers with the spatial tools and technologies required to ignite innovation, and break barriers to advance discovery of new biomarkers and improve treatment options."

"We are excited to partner with Akoya to accelerate multiomic spatial phenotyping in translational and clinical disease research," said Kim Kelderman, President of Bio-Techne’s Diagnostics and Genomics Segment. "Akoya’s established leadership in spatial phenotyping automation and multiplex protein biomarker imaging is uniquely complementary to Bio-Techne’s proven expertise in specific and sensitive multiplex RNA detection in cells and tissues. Enabling Akoya’s large and rapidly growing installed base with an automated HiPlex RNAScope workflow provides a uniquely powerful solution to advance discovery research and diagnostic assay development across a wide range of diseases."

On January 5, 2022 Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") reported a business update for 2022 (Press release, Eagle Pharmaceuticals, JAN 5, 2022, View Source [SID1234598213]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Near-Term Business Highlights:

Vasopressin: The Company will begin shipping its recently approved vasopressin product on Monday, January 17, 2022, with 180 days of marketing exclusivity. This is an important product for Eagle, as Vasostrict U.S. sales totaled $890 million for the LTM ended September 30, 2021.
PEMFEXY: On February 1, 2022, the Company will launch PEMFEXY, a ready-to-use liquid with a unique J-code. Eagle has been building inventory and believes this is a significant opportunity, as the Alimta U.S. market totaled $1.2 billion for the LTM ended September 30, 2021.
TREAKISYM: Eagle’s bendamustine franchise continues to grow, including the launch of the TREAKISYM ready-to-dilute ("RTD") formulation in Japan in the first quarter of 2021. Together with a potential approval of the rapid infusion ("RI") (50ml) liquid formulation, this could generate approximately $20 million of combined royalty and milestone revenue in 2022.
Fulvestrant: Based on discussions with the U.S. Food and Drug Administration ("FDA"), the Company will commence human pilot studies of its fulvestrant product candidate for the treatment of HR+/HER- advanced breast cancer shortly.
Landiolol: The Company is on track to submit a new drug application ("NDA") in the first half of 2022, seeking approval of Landiolol, a novel therapeutic, for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.
CAL02: The Company is preparing to begin clinical trials for CAL02, a novel approach to the treatment of severe bacterial pneumonia, later this year.
"Our business is off to a very strong start this year. With our launch of vasopressin now and PEMFEXY on February 1, we believe that our products will do very well. We are advancing our other pipeline products as we expect to submit an NDA for Landiolol in the first half of this year and to begin our clinical studies for CAL02 later this year. We are also pleased to be moving forward with our fulvestrant product and expect to begin our next clinical studies soon," stated Scott Tarriff, President and Chief Executive Officer of Eagle.

"Importantly, our already-strong balance sheet and cash position will benefit from the two launches and position us well to deploy our cash strategically through additional in-licensing opportunities, as well as potential acquisitions of companies or products," concluded Tarriff.